Open Philanthropy | 2,934,400.00 | 8 | 2018-01 | Scientific research | https://www.openphilanthropy.org/focus/scientific-research/miscellaneous/beth-israel-deaconess-medical-center-clinical-trial-sepsis-therapy | Chris Somerville Heather Youngs | Grant to support Dr. Michael Donnino to conduct a multicenter clinical trial of a therapy for severe sepsis. Announced: 2018-01-30. |
Bill and Melinda Gates Foundation | 4,084,674.00 | 7 | 2017-05-22 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to develop HIV-1 Env based vaccine candidates capable of inducing neutralizing antibodies.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. |
Bill and Melinda Gates Foundation | 594,199.00 | 11 | 2016-11-15 | Global health/Tuberculosis control | https://iatiregistry.org/publisher/bmgf | -- | to determine the capacity of antibodies to protect against naturally-transmitted Mycobacterium tuberculosis (Mtb); Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. |
Bill and Melinda Gates Foundation | -799,336.79 | 16 | 2016-08-02 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to develop novel recombinant adenovirus, plasmid DNA, and mycobacteria vector-based vaccines for HIV-1; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. |
Bill and Melinda Gates Foundation | -250,000.00 | 15 | 2016-04-27 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to continue developing a replicating Ad mosaic HIV-1 vaccine. Replicating Adenovirus Mosaic HIV-1 Vaccine. Investment start date: 11/10/2011 to end date: 9/30/2016. Grantee name: Beth Israel Deaconess Medical Center Inc.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. |
Bill and Melinda Gates Foundation | -3,350,000.00 | 17 | 2015-10-02 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to develop a novel vector/protein HIV-1 Env vaccine for the developing world. Development of Novel Vector/Protein HIV-1 Vaccines. Investment start date: 9/6/2012 to end date: 12/31/2016. Grantee name: Beth Israel Deaconess Medical Center Inc.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. |
Bill and Melinda Gates Foundation | 4,999,946.00 | 6 | 2015-10-02 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to evaluate whether a combination of ART and bNab treatment in HIV-infected individuals could potentially contribute to prolonged and/or lifelong treatment interruption; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. |
Bill and Melinda Gates Foundation | 20,000,356.00 | 1 | 2014-07-18 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to evaluate whether a combination of ART and bNab treatment in HIV-infected individuals could potentially contribute to prolonged and/or lifelong treatment interruption; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. |
Bill and Melinda Gates Foundation | 1,010,000.00 | 10 | 2013-06-03 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to continue developing a replicating Ad mosaic HIV-1 vaccine. Replicating Adenovirus Mosaic HIV-1 Vaccine. Investment start date: 11/10/2011 to end date: 9/30/2016. Grantee name: Beth Israel Deaconess Medical Center Inc.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. |
Bill and Melinda Gates Foundation | 1,063,805.00 | 9 | 2013-04-02 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to generate and to evaluate a clade C SHIV challenge stock. Production of Clade C SHIV Stock. Investment start date: 4/2/2013 to end date: 4/30/2016. Grantee name: Beth Israel Deaconess Medical Center Inc.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. |
Bill and Melinda Gates Foundation | 110,716.00 | 12 | 2013-03-06 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to develop a novel HIV-1 RV144-like vaccine regimen using an improved vaccine vector Mycobacterium bovis Bacillus Calmette-Guerin; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. |
Bill and Melinda Gates Foundation | -110,716.00 | 14 | 2013-03-06 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to develop novel recombinant adenovirus, plasmid DNA, and mycobacteria vector-based vaccines for HIV-1; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. |
Bill and Melinda Gates Foundation | 9,285,024.00 | 4 | 2012-09-06 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to develop a novel vector/protein HIV-1 Env vaccine for the developing world. Development of Novel Vector/Protein HIV-1 Vaccines. Investment start date: 9/6/2012 to end date: 12/31/2016. Grantee name: Beth Israel Deaconess Medical Center Inc.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. |
Bill and Melinda Gates Foundation | 11,890,913.00 | 3 | 2011-11-10 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to continue developing a replicating Ad mosaic HIV-1 vaccine. Replicating Adenovirus Mosaic HIV-1 Vaccine. Investment start date: 11/10/2011 to end date: 9/30/2016. Grantee name: Beth Israel Deaconess Medical Center Inc.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. |
Bill and Melinda Gates Foundation | 8,848,220.00 | 5 | 2011-10-21 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to develop a novel HIV-1 RV144-like vaccine regimen using an improved vaccine vector Mycobacterium bovis Bacillus Calmette-Guerin; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. |
Bill and Melinda Gates Foundation | 100,000.00 | 13 | 2011-04-20 | Global health/malaria | https://iatiregistry.org/publisher/bmgf | -- | to develop a cell phone compatible diagnostic screening device based solely on the principles of magnetic levitation, allowing detection of malaria-infected red blood cells.; Aid type: Project-type interventions. Affected regions: South of Sahara. |
Bill and Melinda Gates Foundation | 18,031,416.00 | 2 | 2006-06-21 | Global health/STD control including HIV/AIDS | https://iatiregistry.org/publisher/bmgf | -- | to develop novel recombinant adenovirus, plasmid DNA, and mycobacteria vector-based vaccines for HIV-1; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified. |